Page last updated: 2024-10-31

mirtazapine and DDPAC

mirtazapine has been researched along with DDPAC in 1 studies

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Research Excerpts

ExcerptRelevanceReference
"In terms of antidepressant drugs prescribed in hospital admission, during stay and discharge, the number of sertraline and venlafaxine prescriptions were associated with the number of VaD patients whilst the number of mirtazapine prescriptions was associated with frontotemporal dementia patients."4.12Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. ( Finn, DP; Joshi, A; McClean, PL; Todd, S; Wong-Lin, K, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Joshi, A1
Todd, S1
Finn, DP1
McClean, PL1
Wong-Lin, K1

Other Studies

1 other study available for mirtazapine and DDPAC

ArticleYear
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals.
    BMC medical informatics and decision making, 2022, 10-07, Volume: 22, Issue:1

    Topics: Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Donepezil; Dothiepin

2022